Anaplastic thyroid cancer – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:16:16 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Anaplastic thyroid cancer – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Safety and Effectiveness of Domvanalimab and Zimberelimab for Adults with Advanced Rare Cancers Resistant to Standard Treatment https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-domvanalimab-and-zimberelimab-for-adults-with-advanced-rare-cancers-resistant-to-standard-treatment/ Wed, 29 Apr 2026 15:05:06 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-domvanalimab-and-zimberelimab-for-adults-with-advanced-rare-cancers-resistant-to-standard-treatment/ This clinical trial is focused on studying the effects of a new treatment combination for patients with advanced forms of five rare cancers. These cancers include peritoneal mesotheliomas, gestational trophoblastic tumors, B3 thymomas and thymic carcinomas, anaplastic thyroid carcinomas, and gastroenteropancreatic neuroendocrine tumors (GEP-NET) and carcinoid tumors. The treatment being tested is a combination of two medications: Domvanalimab and Zimberelimab. Domvanalimab is also known by its code name AB154, and Zimberelimab is referred to as AB122. These medications are designed to work together to help the immune system fight cancer more effectively.

The purpose of the study is to evaluate how well this combination treatment works in patients whose cancers have progressed or become resistant after at least one standard treatment. The study will involve patients receiving the treatment through an intravenous infusion, which means the medication is given directly into a vein. The study will last for a period of up to 24 weeks, during which the effectiveness and safety of the treatment will be closely monitored. Patients will be grouped into different cohorts based on their specific type of cancer, and the study will assess various outcomes, such as the rate of cancer progression and overall survival.

Throughout the study, researchers will collect data to understand how the treatment affects the different types of rare cancers. The goal is to determine if the combination of Domvanalimab and Zimberelimab can provide a new and effective treatment option for patients with these challenging conditions. The study is part of a larger effort to explore innovative therapies for rare cancers, which often have limited treatment options. By participating in this trial, researchers hope to gather valuable information that could lead to improved care for patients with these rare and advanced cancers.

]]> Study of dabrafenib and trametinib combination therapy before and after surgery in patients with BRAF-mutated anaplastic thyroid cancer https://clinicaltrials.eu/trial/study-on-trametinib-and-dabrafenib-for-patients-with-anaplastic-thyroid-cancer/ Wed, 29 Apr 2026 14:58:35 +0000 https://clinicaltrials.eu/trial/study-on-trametinib-and-dabrafenib-for-patients-with-anaplastic-thyroid-cancer/ This study focuses on Anaplastic Thyroid Cancer, which is an aggressive form of thyroid cancer. The treatment being tested combines two medications: dabrafenib and trametinib. These medications are targeted therapies that work together to fight cancer cells in patients who have a specific genetic change called BRAF mutation in their tumor.

The purpose of this research is to determine if giving these medications before surgery can help more patients have successful tumor removal. The treatment plan involves taking both medications by mouth daily. Dabrafenib is taken at a dose of up to 300 mg per day, while trametinib is taken at a dose of up to 2 mg per day. The treatment period may last up to 12 months.

During the study, patients will receive the medications before their planned surgery to help shrink the tumor. After the surgery, patients will continue to take the medications to help prevent the cancer from returning. Throughout the treatment period, doctors will monitor the patients’ health and how well the medications are working.

]]> Study on Sacituzumab Govitecan for Patients with Advanced Differentiated and Anaplastic Thyroid Cancer https://clinicaltrials.eu/trial/study-on-sacituzumab-govitecan-for-patients-with-advanced-differentiated-and-anaplastic-thyroid-cancer/ Wed, 29 Apr 2026 14:57:18 +0000 https://clinicaltrials.eu/trial/study-on-sacituzumab-govitecan-for-patients-with-advanced-differentiated-and-anaplastic-thyroid-cancer/ This clinical trial is focused on studying two types of advanced thyroid cancer: Differentiated Thyroid Carcinoma (DTC) and Anaplastic Thyroid Carcinoma (ATC). The treatment being tested is a medication called sacituzumab govitecan, also known by its code name IMMU-132. This medication is a type of drug called an antibody-drug conjugate, which is designed to target and attack cancer cells. The purpose of the study is to evaluate how effective and safe sacituzumab govitecan is for patients with these types of thyroid cancer.

Participants in the study will receive sacituzumab govitecan through an intravenous infusion, which means the medication is given directly into a vein. The study is organized into two groups, or cohorts, based on the type of thyroid cancer. The first group includes patients with advanced DTC that does not respond to radioactive iodine treatment, while the second group includes patients with advanced ATC. The study will monitor how well the cancer responds to the treatment and any side effects that may occur.

The main goal is to see if sacituzumab govitecan can help reduce the size of the tumors in these patients. Researchers will also look at other factors, such as how long the treatment works and the overall survival of the patients. The study aims to provide an additional treatment option for people with these challenging types of thyroid cancer.

]]>